Cantargia AB (publ) (CANTA.ST)
SEK 1.83
(1.05%)
SEK 1.83
(1.05%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -290.01 Million SEK | 23.99% |
| 2022 | -381.54 Million SEK | -3.05% |
| 2021 | -370.26 Million SEK | -112.86% |
| 2020 | -173.94 Million SEK | -55.88% |
| 2019 | -111.58 Million SEK | -19.59% |
| 2018 | -93.3 Million SEK | -55.49% |
| 2017 | -60 Million SEK | -34.11% |
| 2016 | -44.74 Million SEK | -162.94% |
| 2015 | -17.01 Million SEK | -109.7% |
| 2014 | -8.11 Million SEK | -1.73% |
| 2013 | -7.97 Million SEK | -126.83% |
| 2012 | -3.51 Million SEK | -3.13% |
| 2011 | -3.41 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -43.82 Million SEK | -6.32% |
| 2024 Q1 | -41.22 Million SEK | 42.39% |
| 2023 Q3 | -78.7 Million SEK | -25.68% |
| 2023 Q1 | -77.55 Million SEK | 13.55% |
| 2023 Q4 | -71.54 Million SEK | 9.1% |
| 2023 Q2 | -62.62 Million SEK | 19.25% |
| 2023 FY | -287.76 Million SEK | 24.58% |
| 2022 Q3 | -74.22 Million SEK | 22.68% |
| 2022 FY | -381.54 Million SEK | -3.05% |
| 2022 Q1 | -121.6 Million SEK | -14.99% |
| 2022 Q4 | -89.71 Million SEK | -20.86% |
| 2022 Q2 | -96 Million SEK | 21.05% |
| 2021 Q2 | -86.59 Million SEK | -18.34% |
| 2021 Q1 | -73.17 Million SEK | -29.61% |
| 2021 Q3 | -104.74 Million SEK | -20.96% |
| 2021 Q4 | -105.75 Million SEK | -0.96% |
| 2021 FY | -370.26 Million SEK | -112.86% |
| 2020 FY | -173.94 Million SEK | -55.88% |
| 2020 Q1 | -39.93 Million SEK | -9.63% |
| 2020 Q2 | -37.65 Million SEK | 5.71% |
| 2020 Q3 | -39.89 Million SEK | -5.94% |
| 2020 Q4 | -56.45 Million SEK | -41.52% |
| 2019 Q1 | -23.66 Million SEK | 15.74% |
| 2019 FY | -111.58 Million SEK | -19.59% |
| 2019 Q4 | -36.42 Million SEK | -38.5% |
| 2019 Q3 | -26.3 Million SEK | -4.39% |
| 2019 Q2 | -25.19 Million SEK | -6.49% |
| 2018 Q3 | -21.41 Million SEK | 25.04% |
| 2018 Q1 | -15.25 Million SEK | 7.4% |
| 2018 Q4 | -28.08 Million SEK | -31.15% |
| 2018 Q2 | -28.56 Million SEK | -87.3% |
| 2018 FY | -93.3 Million SEK | -55.49% |
| 2017 FY | -60 Million SEK | -34.11% |
| 2017 Q3 | -11.05 Million SEK | 27.7% |
| 2017 Q2 | -15.29 Million SEK | 11.01% |
| 2017 Q1 | -17.18 Million SEK | -5.86% |
| 2017 Q4 | -16.46 Million SEK | -48.92% |
| 2016 Q2 | -7.92 Million SEK | 2.16% |
| 2016 Q3 | -12.48 Million SEK | -57.55% |
| 2016 Q4 | -16.23 Million SEK | -30.03% |
| 2016 FY | -44.74 Million SEK | -162.94% |
| 2016 Q1 | -8.1 Million SEK | -65.53% |
| 2015 Q4 | -4.89 Million SEK | -56.43% |
| 2015 FY | -17.01 Million SEK | -109.7% |
| 2015 Q3 | -3.12 Million SEK | 42.42% |
| 2015 Q2 | -5.43 Million SEK | -54.56% |
| 2015 Q1 | -3.51 Million SEK | -44.4% |
| 2014 FY | -8.11 Million SEK | -1.73% |
| 2014 Q1 | -1.86 Million SEK | 29.03% |
| 2014 Q3 | -1.97 Million SEK | -8.01% |
| 2014 Q4 | -2.43 Million SEK | -22.94% |
| 2014 Q2 | -1.83 Million SEK | 1.9% |
| 2013 FY | -7.97 Million SEK | -126.83% |
| 2013 Q4 | -2.63 Million SEK | 0.0% |
| 2012 FY | -3.51 Million SEK | -3.13% |
| 2011 FY | -3.41 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | -16.481% |
| Ziccum AB (publ) | -21.56 Million SEK | -1245.162% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -1668.289% |
| BioArctic AB (publ) | 252.64 Million SEK | 214.795% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -34221.538% |
| Mendus AB (publ) | -100.65 Million SEK | -188.144% |
| Genovis AB (publ.) | 54.22 Million SEK | 634.85% |
| Intervacc AB (publ) | -93.57 Million SEK | -209.917% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -1769.63% |
| Active Biotech AB (publ) | -46.48 Million SEK | -523.907% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 1710.4% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -423.336% |
| Aptahem AB (publ) | -10.1 Million SEK | -2770.103% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 9.794% |
| Kancera AB (publ) | -65.04 Million SEK | -345.892% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -115.439% |
| Fluicell AB (publ) | -26.87 Million SEK | -978.972% |
| Saniona AB (publ) | -81.06 Million SEK | -257.759% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -2244.329% |
| Biovica International AB (publ) | -126.07 Million SEK | -130.039% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -582.313% |
| AcouSort AB (publ) | -17.48 Million SEK | -1558.472% |
| Xintela AB (publ) | -57.23 Million SEK | -406.686% |
| Abliva AB (publ) | -96.54 Million SEK | -200.386% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 10.709% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -8174.379% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1723.777% |
| Amniotics AB (publ) | -29.07 Million SEK | -897.548% |
| 2cureX AB (publ) | -36.36 Million SEK | -697.561% |
| CombiGene AB (publ) | -36.3 Million SEK | -698.831% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -1880.99% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 24.553% |
| Camurus AB (publ) | 532.35 Million SEK | 154.478% |
| Corline Biomedical AB | -1.78 Million SEK | -16120.19% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -60.439% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -595.768% |
| I-Tech AB | 24.43 Million SEK | 1286.892% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 63.219% |
| Cyxone AB (publ) | -21.66 Million SEK | -1238.89% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -173.691% |
| Biosergen AB | -27.26 Million SEK | -963.697% |
| NextCell Pharma AB | -43.17 Million SEK | -571.769% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -60.439% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -1596.375% |
| Nanologica AB (publ) | -69.96 Million SEK | -314.529% |
| SynAct Pharma AB | -224.49 Million SEK | -29.186% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -556.504% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -1110.711% |
| LIDDS AB (publ) | -40.67 Million SEK | -613.028% |
| Lipum AB (publ) | -37.25 Million SEK | -678.486% |
| BioInvent International AB (publ) | -369.94 Million SEK | 21.605% |
| Alzinova AB (publ) | -16.52 Million SEK | -1655.338% |
| Oncopeptides AB (publ) | -253.44 Million SEK | -14.429% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -4436.301% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -152.029% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -1340.076% |
| Simris Alg AB (publ) | -36.63 Million SEK | -691.639% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -97.873% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 6.575% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -161.479% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -2407.496% |